Search hospitals > Delaware > Wilmington
Alfred I duPont Hospital for Children
Claim this profileWilmington, Delaware 19803
Global Leader in Leukemia
Global Leader in Tumors
Conducts research for Brain Tumor
Conducts research for Lymphoblastic Leukemia-Lymphoma
Conducts research for Lymphoma
381 reported clinical trials
16 medical researchers
Summary
Alfred I duPont Hospital for Children is a medical facility located in Wilmington, Delaware. This center is recognized for care of Leukemia, Tumors, Brain Tumor, Lymphoblastic Leukemia-Lymphoma, Lymphoma and other specialties. Alfred I duPont Hospital for Children is involved with conducting 381 clinical trials across 624 conditions. There are 16 research doctors associated with this hospital, such as Scott M. Bradfield, Ramamoorthy Nagasubramanian, Emi H. Caywood, and Michael Bober.Area of expertise
1Leukemia
Global LeaderStage II
Philadelphia chromosome positive
BCR-ABL1 positive
2Tumors
Global LeaderStage IV
Stage I
Stage II
Top PIs
Scott M. BradfieldAlfred I duPont Hospital for Children7 years of reported clinical research
Expert in Brain Tumor
Expert in Tumors
43 reported clinical trials
79 drugs studied
Ramamoorthy NagasubramanianNemours Children's Clinic-Jacksonville3 years of reported clinical research
Studies Tumors
Studies Neuroblastoma
28 reported clinical trials
62 drugs studied
Emi H. CaywoodAlfred I duPont Hospital for Children5 years of reported clinical research
Expert in Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
23 reported clinical trials
63 drugs studied
Michael BoberNemours11 years of reported clinical research
Studies Achondroplasia
Studies Rhizomelic Chondrodysplasia Punctata
4 reported clinical trials
3 drugs studied
Clinical Trials running at Alfred I duPont Hospital for Children
Acute Myeloid Leukemia
Brain Tumor
Osteosarcoma
Germ Cell Tumors
Non-Hodgkin's Lymphoma
Langerhans Cell Histiocytosis
Leukemia
Acute Lymphoblastic Leukemia
Rhabdomyosarcoma
Acute Leukemia
Venetoclax + Chemotherapy
for Acute Myeloid Leukemia
This trial is testing whether adding venetoclax to standard chemotherapy can help young patients with relapsed AML. Venetoclax works by blocking a protein that helps cancer cells survive, making it easier for the chemotherapy to kill them. The study aims to find better treatment options for these patients who have limited choices. Venetoclax has been shown to improve overall survival in older and unfit patients with newly diagnosed acute myeloid leukemia when combined with lower intensity therapies.
Recruiting2 awards Phase 34 criteria
Stem Cell Transplantation
for Leukemia
This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical \[haplo\]) versus matched unrelated donors (MUD) in treating children, adolescents, and young adults with acute leukemia or myelodysplastic syndrome (MDS). HCT is considered standard of care treatment for patients with high-risk acute leukemia and MDS. In HCT, patients are given very high doses of chemotherapy and/or radiation therapy, which is intended to kill cancer cells that may be resistant to more standard doses of chemotherapy; unfortunately, this also destroys the normal cells in the bone marrow, including stem cells. After the treatment, patients must have a healthy supply of stem cells reintroduced or transplanted. The transplanted cells then reestablish the blood cell production process in the bone marrow. The healthy stem cells may come from the blood or bone marrow of a related or unrelated donor. If patients do not have a matched related donor, doctors do not know what the next best donor choice is. This trial may help researchers understand whether a haplo related donor or a MUD HCT for children with acute leukemia or MDS is better or if there is no difference at all.
Recruiting2 awards Phase 3
Revumenib + Chemotherapy
for Relapsed/Refractory Leukemia
This phase II trial tests the safety and best dose of revumenib in combination with chemotherapy, and evaluates whether this treatment improves the outcome in infants and young children who have leukemia that has come back (relapsed) or does not respond to treatment (refractory) and is associated with a KMT2A (MLL) gene rearrangement (KMT2A-R). Leukemia is a cancer of the white blood cells, where too many underdeveloped (abnormal) white blood cells, called "blasts", are found in the bone marrow, which is the soft, spongy center of the bones that produces the three major blood cells: white blood cells to fight infection; red blood cells that carry oxygen; and platelets that help blood clot and stop bleeding. The blasts crowd out the normal blood cells in the bone marrow and spread to the blood. They can also spread to the brain, spinal cord, and/or other organs of the body. The leukemia cells of some children have a genetic change in which a gene (KMT2A) is broken and combined with other genes that typically do not interact with one another; this is called "rearranged". This genetic rearrangement alters how other genes are turned on or off in the cell, turning on genes that drive the development of leukemia. Patients with KMT2A rearrangement have higher risk for cancer coming back after treatment. Revumenib is an oral medicine that directly targets the changes that occur in a cell with a KMT2A rearrangement and has been shown to specifically kill these leukemia cells in preclinical laboratory settings and in animals. Drugs used in chemotherapy, such as vincristine, prednisone, asparaginase, fludarabine and cytarabine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial is being done to find out if the combination of revumenib and chemotherapy would be safe and/or effective in treating infants and young children with relapsed or refractory KMT2A-R leukemia.
Recruiting1 award Phase 2
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Alfred I duPont Hospital for Children?
Alfred I duPont Hospital for Children is a medical facility located in Wilmington, Delaware. This center is recognized for care of Leukemia, Tumors, Brain Tumor, Lymphoblastic Leukemia-Lymphoma, Lymphoma and other specialties. Alfred I duPont Hospital for Children is involved with conducting 381 clinical trials across 624 conditions. There are 16 research doctors associated with this hospital, such as Scott M. Bradfield, Ramamoorthy Nagasubramanian, Emi H. Caywood, and Michael Bober.
Where is Alfred I duPont Hospital for Children located?
**Directions to Alfred I duPont Hospital for Children:**
- **From the North or South:** Take I-95 to Exit 8. Follow US 202 North to Route 141, then turn left onto Route 141.
- **Address:** 1600 Rockland Road, Wilmington, DE 19803.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Alfred I duPont Hospital for Children, families can apply through Nemours Children's Health Financial Assistance Program for reduced rates or no charge care for qualifying patients. Contact Nemours Financial Services or visit Nemours.org for application details and guidelines, where financial advocates are also available to assist. For insurance inquiries, reach out to the Patient Accounts department at Dupont Hospital.
What insurance does Alfred I duPont Hospital for Children accept?
The Alfred I duPont Hospital for Children accepts various insurance plans, including Highmark Blue Cross Blue Shield of Delaware and Highmark of Pennsylvania through the BlueCard program. Horizon Blue Cross Blue Shield of New Jersey terminated its hospital contract with Nemours/Alfred I duPont Hospital for Children in 2014, making it out of network for Horizon BCBSNJ members. Nemours Children's Health accepts many types of insurance plans; however, it's crucial to check with your insurance provider regarding coverage for specific services.
What awards or recognition has Alfred I duPont Hospital for Children received?
Alfred I. duPont Hospital for Children in Wilmington, Delaware, is renowned for its research and care in chronic and rare childhood diseases. Supported by the Nemours Foundation since 1936, it has achieved Magnet status multiple times and is consistently ranked by U.S. News & World Report’s Top Children’s Hospital awards. The hospital also offers biomedical research fellowship training and undergraduate summer scholarship programs for medical students.